trending Market Intelligence /marketintelligence/en/news-insights/trending/b8fxke9aukt2pquk27wadw2 content esgSubNav
In This List

CytRx closes $7M direct offering of common shares

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


CytRx closes $7M direct offering of common shares

CytRx Corp. closed its direct offering of 5.6 million common shares at $1.25 apiece to raise $7.0 million in gross proceeds.

The company received about $6.5 million in net proceeds from the offering.

CytRx plans to use the net proceeds for working capital and general corporate purposes, including possible new drug discovery activities and acquisitions or mergers.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Los Angeles, Calif.-based CytRx is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor.